{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-005198","form_type":"8-K","ticker":"SRZN","cik":"0001824893","company_name":"Surrozen, Inc./DE","filed_at":"2024-01-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.762284+00:00","generated_at":"2026-06-06T22:03:50.269135+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Surrozen discontinues SZN-1326; SZN-043 Phase 1a complete, data due Q1 2024","bullets":["SZN-043 Phase 1a enrollment in chronic liver disease and healthy volunteers complete; safety/pharmacodynamic data expected Q1 2024.","Phase 1b for alcohol-associated hepatitis to initiate soon; proof-of-concept data possible in H2 2024.","SZN-1326 development in IBD discontinued due to asymptomatic grade 3 ALT/AST elevations at high doses and strategic factors.","No serious adverse events in SZN-1326 trial; transaminase elevations resolved spontaneously in all subjects."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-005198","json":"https://secwatch.observer/filing/0000950170-24-005198.json","markdown":"https://secwatch.observer/filing/0000950170-24-005198.md","text":"https://secwatch.observer/filing/0000950170-24-005198.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824893/000095017024005198/0000950170-24-005198-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824893/000095017024005198/srzn-20240118.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T22:03:50.269135+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}